Fenbendazole

Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53^[1]. In Vitro:Fenbendazole (1 uM; for 24 h) significantly reduces cell growth in tumour cell lines with wild-type p53, H460 and A549 human NSCLC cell lines^[1].
Fenbendazole (1 uM; for 24 h) induces apoptosis and causes an increased level of p53 protein in the mitochondrial fraction^[1].
Fenbendazole (1 uM; for 24 h) causes cell cycle arrest in the mitotic phase in human NSCLC cells^[1].
Fenbendazole (1 uM; for 24 h) causes a partial alteration of the microtubule network in human non small cell lung carcinoma (NSCLC) A549 cells^[1].
In Vivo:Fenbendazole (1 mg; orally; every second day for 12 day) leads to a marked reduction in tumour size and weight^[1].